ArticleArthritis care & research2026
Association of Vaccination With COVID Outcomes in Pregnant People With Autoimmune Diseases: A Retrospective National Cohort Analysis.
Article in Arthritis care & research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveTo evaluate the effectiveness of COVID-19 vaccination in reducing incident and severe COVID-19 among pregnant individuals with autoimmune rheumatic diseases (AIRDs).
methodsWe conducted a retrospective cohort study using national electronic health records, including 270,811 pregnant individuals aged 15 to 55 years with pregnancies between December 10, 2020, and June 1, 2024. Among them, 4,715 (1.5%) had at least one AIRD (rheumatoid arthritis, spondyloarthritis, or systemic lupus erythematosus). Participants were categorized by AIRD and vaccination status (unvaccinated, initially vaccinated, or booster vaccinated). Time to incident and severe COVID-19 was assessed using adjusted time ratios (TRs), stratified by variant period (pre-Omicron vs Omicron).
resultsInitial vaccination delayed time to COVID-19 during the pre-Omicron period in individuals with AIRDs (TR: 1.095; 95% confidence interval [CI]: 1.036-1.157) but not during Omicron (TR: 1.039; 95% CI: 0.980-1.102). Booster vaccination was not significantly protective against infection (TR: 1.039; 95% CI: 0.958-1.128) or severe outcomes (TR: 1.119; 95% CI: 0.670-1.867). Compared to vaccinated individuals without AIRDs, those with AIRDs had shorter time to breakthrough infections in both pre-Omicron (TR: 0.940; 95% CI: 0.891-0.991) and Omicron (TR: 0.905; 95% CI: 0.858-0.955) periods and to severe disease during Omicron (TR: 0.631; 95% CI: 0.485-0.821).
conclusionVaccination is associated with protection against COVID-19 in pregnancy, but its effectiveness is reduced in those with AIRDs, particularly during the Omicron period.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.